Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Pharmacy exec in plea deal in Michigan over 2012 meningitis outbreak deaths

Published 03/05/2024, 04:26 PM
Updated 03/05/2024, 08:07 PM
© Reuters. FILE PHOTO: Pharmacist and co-founder of the now-defunct New England Compounding Center Barry Cadden walks to his car after being sentenced to nine years in jail, beginning in August, for his role in a deadly U.S. meningitis outbreak in 2012, in Boston, M

By Nate Raymond

(Reuters) - A former owner of a Massachusetts compounding pharmacy whose mold-tainted drugs sparked a deadly U.S. fungal meningitis outbreak in 2012 has pleaded no contest to involuntary manslaughter charges over the deaths of 11 Michigan residents.

The plea by Barry Cadden, the former president of New England Compounding Center, was announced on Tuesday by Michigan Attorney General Dana Nessel and resolves a criminal case her office brought against him in state court in 2018.

The state's charges came after federal juries in Boston in 2017 convicted Cadden and NECC's supervisory pharmacist, Glenn Chin, of racketeering and fraud but cleared them of second-degree murder over 25 deaths nationally caused by tainted drugs the company produced.

Prosecutors said those deaths stemmed from a fungal meningitis outbreak traced back to mold-tainted steroids that Framingham, Massachusetts-based NECC produced in filthy and unsafe conditions and sold to hospitals and clinics nationally.

The outbreak sickened 793 patients, more than 100 of whom have died, prosecutors said.

Prosecutors in Michigan, a state that was among the hardest hit during the outbreak, following the federal trials then charged Cadden and Chin with 11 counts each of second-degree murder over deaths in their state.

Nessel in a statement said her office "worked closely with the families of these victims, and we’ve ensured that this plea fits their desire for closure and justice."

Under the terms of the plea deal, Cadden, 57, on Monday pleaded no contest to manslaughter charges and agreed to be sentenced to 10 to 15 years in prison, which would run concurrently with his already-imposed federal sentence of 14-1/2 years.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

That federal sentence relates to misrepresentations that prosecutors say Cadden made to NECC customers about its drugs.

He is scheduled to be sentenced by a judge in Livingston County, Michigan, on April 18. A lawyer for Cadden did not immediately respond to a request for comment.

Charges in Michigan remain pending against Chin, who has pleaded not guilty and is serving a 10-1/2 year federal sentence. His lawyer declined to comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.